
Antibodiesinc/TRIP8b (constant)/75-243/1 Ea
商品编号:
75-243
市场价:
¥0.00
美元价:
0.00
产品分类:
重组抗体
公司分类:
Recombinant_antibodies
联系Q Q:
3392242852
电话号码:
4000-520-616
电子邮箱:
info@ebiomall.com
商品介绍
Fusion protein amino acids 1-192 (exon 1a, exon 4 and constant region) of rat TRIP8b
(also known as TPR-containing Rab8b-interacting protein, Peroxisome biogenesis factor 5-like, Peroxin-
5- or PEX5-related/like protein, Pex5Rp, Pex5l, Pex5r, Pex2, Pxr2, accession number Q925N3)
Mouse: 97% identity (147/151 amino acids identical)
Human: 83% identity (180/216 amino acids identical)
(also known as TPR-containing Rab8b-interacting protein, Peroxisome biogenesis factor 5-like, Peroxin-
5- or PEX5-related/like protein, Pex5Rp, Pex5l, Pex5r, Pex2, Pxr2, accession number Q925N3)
Mouse: 97% identity (147/151 amino acids identical)
Human: 83% identity (180/216 amino acids identical)
Specifications:
Target |
![]() |
TRIP8b (constant) |
![]() |
||
Channel Target |
![]() |
Other Ion Channels |
![]() |
||
Applications |
![]() |
Immunoblot (IB) Immunocytochemistry (ICC) Immunohistochemistry (IHC) |
![]() |
||
Clone |
![]() |
N212/7 |
![]() |
||
IgG Isotype |
![]() |
IgG2b |
![]() |
||
Species Reactivity |
![]() |
Human (H) Mouse (M) Rat (R) |
![]() |
||
Validation |
![]() |
Br-IB Br-IHC T |
![]() |
||
Type |
![]() |
Purified |
![]() |
||
Format |
![]() |
100 ul |
![]() |
||
Cross Reactivity |
![]() |
Cross-reacts with multiple TRIP8b isoforms |
![]() |
||
Expected Banding Pattern |
![]() |
70 kDa |
![]() |
||
Host |
![]() |
Mouse (M) |
![]() |
||
Label |
![]() |
Unlabeled |
![]() |
||
Antibody Type |
![]() |
Monoclonal |
![]() |
||
Commercial Price |
![]() |
450 |
![]() |
||
Non-Profit Price |
![]() |
200 |
![]() |
||
Distributor Price |
![]() |
Per Contract(QUOTE) |
![]() |
||
ABID |
![]() |
RRID:AB_10675329 |
![]() |
品牌介绍
当抗体公司(Antibodies Incorporated)在1962年开业时,与抗体相关的研究才刚刚开始。创始人Jim Hillman拥有博士学位。从药理学明尼苏达大学,来到加州大学戴维斯分校在免疫化学完整的博士后工作,在工作期间,他学习了加州理工学院(加州理工学院)根据丹·坎贝尔,领域的先驱。吉姆带来了他的妻子,公司的共同创始人卡罗尔(Carol)和两个孩子,以及使用基于抗体的化学疗法寻找治疗癌症的能量和想法。具体地说,吉姆认为,如果他能够识别并分离出可能具有抗原性的肿瘤部位(一个焦点是淋巴肉瘤),则可能有可能进行有效的基于抗体的治疗。吉姆寻找这种治疗方法的梦想推动了他的工作多年。